<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104363">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02118961</url>
  </required_header>
  <id_info>
    <org_study_id>BKD1A</org_study_id>
    <nct_id>NCT02118961</nct_id>
  </id_info>
  <brief_title>Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents</brief_title>
  <official_title>Confirmatory Study to Evaluate the Immunogenicity of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP Vaccine, BK1301) as a Booster in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Foundation for Microbial Diseases of Osaka University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a
      booster dose in adolescents.

      The purposes of this study are as follows:

        -  To confirm the non-inferiority of BK1301 to Adsorbed Diphtheria-Tetanus Combined Toxoid
           (DT toxoid) with respect to booster responses for anti-diphtheria toxoid (anti-D) and
           anti-tetanus toxoid (anti-T) antibodies

        -  To confirm that booster responses for anti-pertussis toxoid (anti-PT) and
           anti-Filamentous Hemagglutinin (anti-FHA) antibodies are more than 80% of participants
           received BK1301
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percentage of participants with booster responses for anti-D and anti-T antibodies</measure>
    <time_frame>pre-vaccination and 28-42 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with booster responses for anti-PT and anti-FHA  antibodies</measure>
    <time_frame>pre-vaccination and 28-42 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with anti-D and anti-T antibody titers above protocol defined cut-off values</measure>
    <time_frame>28-42 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with anti-PT and anti-FHA antibody titers above protocol defined cut-off values</measure>
    <time_frame>28-42 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titers (GMTs) of anti-D and anti-T antibodies</measure>
    <time_frame>28-42 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs of anti-PT and anti-FHA antibodies</measure>
    <time_frame>28-42 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in GMTs of anti-D and anti-T antibodies</measure>
    <time_frame>pre-vaccination and 28-42 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in GMTs of anti-PT and anti-FHA antibodies</measure>
    <time_frame>pre-vaccination and 28-42 days after vaccination</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Adverse Events</measure>
    <time_frame>28-42 days following vaccination</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>BK1301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DT toxoid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)</intervention_name>
    <description>0.5 mL, subcutaneous injection</description>
    <arm_group_label>BK1301</arm_group_label>
    <other_name>TRIBIK®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)</intervention_name>
    <description>0.1 mL, subcutaneous injection</description>
    <arm_group_label>DT toxoid</arm_group_label>
    <other_name>DTBIK®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 11 or 12 years on the day of injection

          -  Received 3 or 4 doses of DTaP vaccine

        Exclusion Criteria:

          -  History of pertussis, diphtheria, tetanus

          -  History of anaphylaxis to vaccine components

          -  Serious conditions or diseases of the heart, vein, blood, respiratory, hepar, kidney,
             digestive system, psychiatric or nervous system

          -  Transfused or received gamma globulin within 3 months, or received high-dose gamma
             globulin within 6 months before the day of injection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shintaro Okada, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Osaka University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development R&amp;D</last_name>
    <email>crdcontact@mail.biken.or.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Trials Information Desk</last_name>
    <email>cti-inq-ml@ml.mt-pharma.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Itoshima-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Kasuga-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inverstigational site</name>
      <address>
        <city>Kumagaya-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Shizuoka-shi</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inverstigational site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>April 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <keyword>DTaP vaccine</keyword>
  <keyword>Adolescents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Tetany</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
